UNSPSC 51162000: Combination antiasthma agents

This classification denotes combination drugs that treat a bronchial disorder with three distinct components: airway hyper-responsiveness, airway inflammation, and intermittent airway obstruction, the disease called ASTHMA. it is characterized by spasmodic contraction of airway smooth muscle, wheezing, and dyspneabronchial disorder with three distinct components: airway hyper-responsiveness (respiratory hypersensitivity), airway inflammation, and intermittent airway obstruction. it is characterized by spasmodic contraction of airway smooth muscle, wheezing, and dyspnea.

Typical combination antiasthma agent constituents are albuterol, aminophylline, dyphylline, ephedrine, fluticasone, and formoterol.

UNSPSC 51162000 Combination antiasthma agents is a Class code that in practice encompasses a broader range of pharmaceutical products and pharmacy services than its nominal scope suggests—recent state and local solicitations under this code include naloxone procurement, on-site pharmacy benefit management, direct-to-manufacturer prescription programs, and generic pharmaceutical supply agreements. State and local governments buying under the code span county health departments, county employee health benefit programs, state health agencies, and multistate cooperative purchasing consortia. Seminole County, Florida; Hall County, Georgia; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) all posted opportunities here in the past four months, indicating that pharmacy procurement draws from multiple jurisdictional levels and organizational models—from small county health initiatives to large multi-state purchasing cooperatives managing pharmaceutical supply across dozens of participant jurisdictions.

Activity concentrates in Florida, Georgia, Texas, and Minnesota, with the MMCAP opportunity extending reach to Oregon and other cooperative-member states. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building; Hall County's RFQ/P #47-010 (posted May 4, 2026, due June 4, 2026) seeking an on-site pharmacy services provider to dispense a 25-medication formulary to approximately 3,005 county employees and dependents at the Hall County Government Family Health Center Clinic; and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (posted January 20, 2026, due March 26, 2026), which establishes multi-award contracts for manufacturers supplying through three authorized wholesalers to participating state and local facilities. The Texas Health and Human Services Commission also issued a Request for Information on April 3, 2026, exploring direct-to-manufacturer prescription programs outside traditional PBM and GPO channels, signaling emerging state interest in alternative pharmacy benefit models.